“It’s that invisible illness”: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment

Knowledge of what outcomes are most meaningful to pulmonary arterial hypertension (PAH) stakeholders is limited. In this qualitative study, patients and clinicians endorsed personalized physical activity, symptoms, and psychosocial well-being as key outcomes to assess PAH treatment response, yet few are routinely measured in PAH clinical trials.

National Institutes of Health
National Heart, Lung , and Blood Institute
Janssen Pharmaceutical Companies of Johnson and Johnson